Evidence map›Paper›PMID 31002925›Full record

ReviewMechanisms of ageing and development2019

Frailty biomarkers in humans and rodents: Current approaches and future advances.

Alice E Kane, David A Sinclair

Open access · greenAbstract readReview
In one paragraph

Review in Mechanisms of ageing and development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. High frailty index scores predict mortality and changes in blood-based biomarkers in aging female mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  3. Developing and internally validating AI-based aging resilience biomarkers in non-human primates.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Social and clinical frailty indices in aging mice: a comparative analysis of longitudinal and cross-sectional designs.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Animal Models Relevant for Geroscience: Current Trends and Future Perspectives in Biomarkers, and Measures of Biological Aging.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Review
  18. Article
  19. Review
  20. Identification of novel FRedox biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alice E KaneDepartment of Genetics, Harvard Medical School, Boston, MA, USA; Charles Perkins Centre, The University of Sydney, Sydney, Australia. Electronic address: alice_kane@hms.harvard.edu.
David A SinclairDepartment of Genetics, Harvard Medical School, Boston, MA, USA; Department of Pharmacology, The University of New South Wales, Sydney, Australia. Electronic address: david_sinclair@hms.harvard.edu.
University of Sydney · AUUNSW Sydney · AU

Funding

Uncovering the Human SecretomeDP1AG058605 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2017 to 2021
$5.9M
Role of Sgs1 DNA helicase in telomere maintenanceR01AG019719 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SINCLAIR, DAVID A. · 2001 to 2022
$5.3M
SIRT1 as a regulator of health and lifespan of mammalsR37AG028730 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2012 to 2021
$4.1M
Elucidating mechanisms of SIRT1 activationR01DK100263 · NIDDK · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2016 to 2020
$2.5M
SIRT as a regulator of health and lifespan of mammalsR01AG028730 · NIA · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2007 to 2011
$1.7M
Nicotinamide Mononucleotide (NMN) as a Novel Therapeutic in the Treatment of Oral MucositisR21DE027490 · NIDCR · HARVARD MEDICAL SCHOOL · PI SINCLAIR, DAVID A. · 2018 to 2019
$466k
NIA NIH HHS DP1 AG058605NIA NIH HHS R01 AG019719NIA NIH HHS R01 AG028730NIA NIH HHS R37 AG028730NIDCR NIH HHS R21 DE027490NIDDK NIH HHS R01 DK100263
6 · The paper itself

Abstract

Even though they would have great benefit across research and clinical fields, currently there are no accepted biomarkers of frailty. Cross-sectional studies in humans have identified promising candidates including inflammatory markers such as IL-6, immune markers such as WBC count, clinical markers such as albumin, endocrine markers such as vitamin D, oxidative stress markers such as isoprostanes, proteins such as BDNF and epigenetic markers such as DNA methylation, but there are limitations to the current state of the research. Future approaches to the identification of frailty biomarkers should include longitudinal studies, studies using animal models of frailty, studies incorporating novel biomarkers combined into composite panels, and studies investigating sex differences and potential overlap between markers of biological age and frailty.

Indexed as

DNA MethylationEpigenesis, GeneticAgingAnimalsBiomarkersBrain-Derived Neurotrophic FactorFemaleFrailtyHumansInflammation MediatorsInterleukin-6MaleMiceRatsBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorIL6 protein, humanInflammation MediatorsInterleukin-6AgingAnimal modelsBiological ageDeficit accumulationEpigeneticsSex differences

Identifiers

PMID31002925
PMCPMC6581034
OpenAlexW2939373830

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.